Adlai Nortye (ANL) Accumulated Expenses (2022 - 2025)
Adlai Nortye's (ANL) quarterly Accumulated Expenses came in at $3.1 million in Q4 2025, up 2.64% year-on-year from $3.1 million in Q4 2024, and up 2.64% on a QoQ basis from $3.1 million in Q4 2024.
Adlai Nortye (ANL) Accumulated Expenses (2022 - 2025) Analysis & Trends
Adlai Nortye (ANL) has 4 years of Accumulated Expenses data on file, last reported at $3.1 million in Q4 2025.
- On a quarterly basis, Accumulated Expenses rose 2.64% year-over-year to $3.1 million in Q4 2025; TTM through Dec 2025 was $3.1 million, a 2.64% increase from a year earlier, with the FY2025 full-year figure at $3.1 million, up 2.64% from the prior year.
- Accumulated Expenses for Q4 2025 stood at $3.1 million, up from $3.1 million in the prior quarter.
- Over the last five years, Accumulated Expenses for ANL reached as high as $3.8 million in Q4 2023 and fell as low as $3.1 million in Q4 2024.
- Historically, Accumulated Expenses has averaged $3.4 million across 4 years, with a median of $3.4 million in 2022.
- Across the five-year window, Accumulated Expenses gained 5.3% in 2023 and slipped 19.69% in 2024, its largest moves.
- Year by year, Accumulated Expenses stood at $3.6 million in 2022, then gained by 5.3% to $3.8 million in 2023, then slipped by 19.69% to $3.1 million in 2024, then gained by 2.64% to $3.1 million in 2025.
- Per Business Quant data, the three most recent Accumulated Expenses figures were $3.1 million in Q4 2025, $3.1 million in Q4 2024, and $3.8 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Adlai Nortye | 1.16 Bn | 1.15 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.14 Mn |
| Dec 31, 2024 | 3.06 Mn |
| Dec 31, 2023 | 3.81 Mn |
| Dec 31, 2022 | 3.62 Mn |